The IMMray PanCan-d test measures 9 serum biomarkers, including CA19-9, that when combined in an algorithm is able to detect pancreatic ductal adenocarcinoma. The biomarkers are a combination of immunoregulatory and tumor biomarkers.
The test relies on the IMMray microarray technology, where single chain fragment antibodies are printed onto a slide in a measured amount as a microarray of different antibody biomarkers.
When a patient’s serum sample is received at Immunovia, Inc., the serum is biotinylated and applied to the microarray. The microarray is scanned using a fluorescence scanner to measure the serum response to each biomarker. A separate CA19-9 test is performed. The values for each biomarker (including CA19-9) are then entered into proprietary computer software, which uses an algorithm to determine a result of High-Risk Signature Present, Negative for High-Risk Signature or Borderline.
IMMray PanCan-d incorporates biomarker technology licensed from JW BioScience Corporation.
